NCT00736294View on ClinicalTrials.gov

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

PHASE3TerminatedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Atrial FibrillationAtrial Flutter
Interventions
DRUG

Ramipril

5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets

DRUG

Placebo

5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets

Trial Locations (8)

29609

CHU de Brest, Brest

34295

CHU de Montpellier, Montpellier

35033

CHU de Rennes, Rennes

38043

CHU de Grenoble, Grenoble

63003

CHU de Clermont-Ferrand, Clermont-Ferrand

76031

CHU de Rouen, Rouen

83190

Polyclinique des Fleurs, Ollioules

42 055

CHU de Saint-Etienne, Saint-Etienne

Sponsors

Collaborators (2)

Sanofi
LivaNova
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Ministry of Health, France

OTHER_GOV

collaborator

LivaNova

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT00736294 - Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter | Biotech Hunter | Biotech Hunter